FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Instruc	tion 1(b).			File					a) of the Se Investmen					34		liouis	per rec		0.0
Name and Address of Reporting Person* Smith Michael David				2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]									eck all applic Directo	tor 10% O		wner			
(Last) (First) (Middle) C/O KALVISTA PHARMACEUTICALS, INC 55 CAMBRIDGE PARKWAY, SUITE 901E					3. Date of Earliest Transaction (Month/Day/Year) 12/16/2020								below)	Officer (give title below) Other (specify below) Senior VP, Development					
(Street) CAMBRIDGE MA 02142					4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				ı		
(City)	(S		(Zip)	. Danie		- 0-		- ^ -	i al	D:			D		0				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			2A. Deemed Execution Date,		3. 4. Securit Transaction Disposed Code (Instr. 5)		ities Acquired (A) d Of (D) (Instr. 3, 4		(A) or	5. Amour Securitie Beneficia Owned F Reported	nt of 6.0 For ally (I) (I) (I) (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
										V	Amount	(1	A) or D)	Price	Transact (Instr. 3 a				
		-	Table II - I						uired, D , option						Owned				
1. Title of Derivative Security (Instr. 3)			ransaction of lode (Instr. Derivative (6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
		- 1		1		I	- 1		I		amount	I	I			1			

Explanation of Responses:

\$10.2

1. Represents performance stock options granted to the Reporting Person on June 16, 2020. As a result of the Reporting Person having met the applicable performance criteria, 1/48 of the total stock options vests monthly over a 4-year period commencing on December 16, 2020 until fully vested, subject to the Reporting Person's continued service through each vesting date.

Date Exercisable

(1)

Expiration Date

06/16/2030

Title

Common

Stock

Remarks:

Stock Option

(right to

buy)

/s/ Benjamin L. Palleiko

or Number

of Shares

25,000

\$0.00

12/18/2020

25,000

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

12/16/2020

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A⁽¹⁾

(A)

25,000

(D)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.